Study record

Reduced skeletal muscle expression of mitochondrial-derived peptides humanin and MOTS-C and Nrf2 in chronic kidney disease

Liu C, Gidlund EK, Witasp A et al. · Am J Physiol Renal Physiol · 2019

Human obs.Endogenous MOTS-c measuredEvidence tier B

What this study reported

Found lower MOTS-c in both skeletal muscle and serum of patients with stage 5 CKD than in controls, whereas circulating humanin was higher and muscle humanin lower. Reduced muscle MDP levels were associated with lower mitochondrial density and evidence of oxidative stress.

Limitations

Cross-sectional comparison; sample size not reported in the abstract; restricted to advanced CKD.

Study record

Annotated fields for this study
Study modelHuman observational
Substance studiedEndogenous MOTS-c measuredNaturally occurring MOTS-c was measured; nothing was given.
Specieshuman
System studiedSkeletal muscle and serum from patients with stage 5 chronic kidney disease and age-matched controls
Populationpatients with stage 5 chronic kidney disease and age-matched controls with normal renal function
DesignCase-control study
Sample size as reportedNot reported
Control groupage-matched controls with normal renal function
Route (data field only)Not reported
Endpoints measuredskeletal muscle MOTS-c and humanin protein; serum MOTS-c and humanin; mitochondrial density; oxidative stress markers; circulating TNF
Pathways measuredNRF2 / antioxidant response · Oxidative stress · Inflammation
Research areasKidney · Skeletal muscle · Aging · Mitochondrial biology
Evidence tierB — Other human study
Publication typesJournal Article

Appraisal

Each dimension is recorded separately and never combined into a single score. A study can be well controlled and still tell you little about people.

Relevance to MOTS-c
Direct
Model applicability
Human
Sample size
Not reported
Controls
Appropriate
Outcome validity
Validated biomarker
Support for its own conclusion
Moderate

Provenance

  • Bibliographic fields retrieved from PubMed E-utilities efetch (title, journal, date, authors, DOI) on 2026-11-11.
  • Annotated from the published abstract.
  • Editorial review: approved (2026-11-11).
  • Classification follows the site methodology; the record describes the study, not what MOTS-c does in people.